Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 919,936 shares, a growth of 4,905.1% from the September 30th total of 18,380 shares. Approximately 89.7% of the shares of the company are short sold. Based on an average daily volume of 7,171,805 shares, the short-interest ratio is presently 0.1 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings upgraded shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 14th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Biodexa Pharmaceuticals has an average rating of “Sell”.
Read Our Latest Analysis on Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Stock Up 9.0%
BDRX traded up $0.30 during trading hours on Monday, hitting $3.69. The company’s stock had a trading volume of 40,694 shares, compared to its average volume of 228,197. Biodexa Pharmaceuticals has a fifty-two week low of $2.70 and a fifty-two week high of $357.60. The company has a 50-day simple moving average of $0.77 and a 200 day simple moving average of $2.12.
Biodexa Pharmaceuticals Company Profile
Biodexa Pharmaceuticals plc, formerly known as Midatech Pharma plc, is a biopharmaceutical company focused on developing medicines for diseases with significant unmet medical needs. The company’s work has centered on oncology, rare diseases and conditions that are difficult to treat with conventional drug-delivery methods.
Biodexa’s development programs have included MTX110, a proprietary aqueous formulation of panobinostat being investigated for direct administration into brain tumors, including diffuse intrinsic pontine glioma.
Further Reading
- Five stocks we like better than Biodexa Pharmaceuticals
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Biodexa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodexa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
